Related Articles
Survivor’s guilt: what it is and how to manage it
Experiencing guilt after cancer treatment may sound unexpected, but it’s actually quite common. Clinical psychologist Catherine Powers, Ph.D., and senior social work counselor Kendolyn Shankle…
A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Advances in Therapy – According to current guidelines, targeted therapy with a combination of BRAF plus MEK inhibitors is the preferred first-line treatment for patients…
Retrospective Claims Data and Patient Reported-Outcomes from COMMANDS Trial in Lower-Risk MDS
Amy DeZern, MD, MHS, discusses a retrospective study on healthcare claims for patients with MDS treated with luspatercept and reviews patient-reported outcomes from the COMMANDS…
Utilizing Sports Events to Spread Awareness of Ovarian… : Oncology Times
An abstract is unavailable.
Biomarker-Focused Strategies Improve Outcomes in Gynecologic Malignancies
Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.
Giants of Cancer Care® Announces the 12th Annual Class of Inductees
The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.
Homing in on Currently Recruiting Clinical Trials With Practice Changing Implications in Lymphoma and Myeloma
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
Ekspert FDA: przyspieszona lub warunkowa rejestracja jest możliwa. Ale leki nieskuteczne można usunąć z rynku
Agencje rejestrujące leki, takie jak FDA czy EMA, mogą dopuszczać leki w procedurze przyspieszonej lub warunkowo. Bywa, że jeśli lek okaże się nieskuteczny, może zostać…
Ongoing Research Drives Further Questions in Early-Stage Breast Cancer Management
Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.
Radiation doses received by major organs at risk in children and young adolescents treated for cancer with external beam radiation therapy: a large-scale study from 12 European countries.
Childhood cancer survivors are at high risk of long-term iatrogenic events, in particular those treated with radiotherapy. The prediction of risk of such events is…